SwingTrade Member Forum

[RIGATONI]

NEOP News...........

NEOP news - News from Neoprobe Corporation: Quantix/ND Neurosurgery Clinical Results Published and Presented
Friday September 12, 8:30 am ET
New Technology Permits Bedside Assessment of Blood Flow


DUBLIN, Ohio--(BUSINESS WIRE)--Sept. 12, 2003--Neoprobe Corporation (OTCBB:NEOP - News), today announced that the results of a clinical evaluation using its proprietary blood flow measurement technology were published in the peer review journal Stroke. The article reported the clinical evaluation of patients at University of California at Los Angeles (UCLA) Medical Center in the Division of Neurosurgery. The researchers concluded that the study supported the implementation of new technology in the bedside assessment of cerebral hemodynamics in critically ill neurosurgery patients. The UCLA study evaluated the first generation of Neoprobe's Cardiosonix Quantix/ND(TM) system for the determination of blood flow volume (BFV) in the internal carotid artery (ICA).
The author of the paper, Dr. Jean F. Soustiel of the Rambam Medical Center in Haifa, Israel, stated, "BFV measurements with this new technology proved to accurately correlate with the cerebral blood flow (CBF) values evaluated by (133)xenon-clearance technique. The results of the study support the implementation of the measurement of ICA BFV with the Quantix/ND for the bedside assessment of cerebral hemodynamics in the critically ill patient."

Dr. Neil Martin of the UCLA Division of Neurosurgery stated that, "the results of the present study show that ICA BFV can be reliably measured and monitored in critically ill patients, with a close correlation with CBF values. The Quantix technology permits the non-invasive bedside estimation of CBF that may facilitate a more clear understanding of cerebral hemodynamics. The Quantix/ND is now routinely utilized for monitoring patients admitted to the Brain Injury Research Center at UCLA."

In addition, Quantix/ND researchers, including Dr. Ralf Rothoerl of Germany, presented a variety of papers at the 12th European Congress of Neurosurgery held in Lisbon from September 8th through 11th. The papers demonstrated the accuracy of non-invasive measurement of ICA blood flow with the Quantix/ND and of the patient treatment decision-making that could be made with this innovative bedside technology. Dr. Rothoerl stated, "the Quantix/ND provided an effective means of determining ICA flow in monitoring patients with either hyperemia or ischemia."

The Quantix/ND is designed to allow neurosurgeons and vascular surgeons, as well as intensive care unit or emergency room physicians, to non-invasively assess global cerebral blood flow in a simple and real-time manner. Quantix/ND consists of an angle-independent ultrasound probe that obtains signals directly from the carotid artery. Quantix/ND is designed primarily for use in monitoring head trauma patients in neuro-intensive care units and emergency rooms. In addition to neurosurgery applications, the Quantix/ND can be used to measure blood flow in vascular assessment applications such as femoral artery perfusion.

About Neoprobe

Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe's current line of gamma detection systems is widely used for intraoperative lymphatic mapping (ILM), an emerging standard of care technology for breast cancer and melanoma and the detection of radiopharmaceuticals applied throughout the human body's tissues and organs. Neoprobe also holds significant interests in the development of related biomedical systems and agents. The Company's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. With the 2001 acquisition of Cardiosonix Ltd., Neoprobe expanded its product portfolio to include blood flow measurement products. Cardiosonix is engaged in the early stages of commercializing the Quantix(TM) family of flood flow measurement products. Cardiosonix' products are designed to be used by neurosurgeons, cardiovascular surgeons and critical care physicians.

Statements in this news release which relate to other than strictly historical facts are forward-looking statements, and as such are subject to risks and uncertainties, including those detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.



--------------------------------------------------------------------------------
Contact:
Neoprobe Corporation
Brent L. Larson, 614-793-7500
or
The Trout Group
Jonathan Fassberg, 212-437-9007

Rig